ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc (AVIR)

4.04
0.04
(1.00%)
At close: March 28 04:00PM
4.04
0.04
( 1.00% )
After Hours: 05:57PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
4.04
Bid
3.91
Ask
4.05
Volume
374,018
3.98 Day's Range 4.09
2.765 52 Week Range 5.19
Market Cap
Previous Close
4.00
Open
3.98
Last Trade
1
@
3.91
Last Trade Time
18:49:28
Financial Volume
$ 1,512,779
VWAP
4.0447
Average Volume (3m)
494,742
Shares Outstanding
84,164,545
Dividend Yield
-
PE Ratio
-2.49
Earnings Per Share (EPS)
-1.62
Revenue
-
Net Profit
-135.96M

About Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treat... Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Atea Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AVIR. The last closing price for Atea Pharmaceuticals was $4. Over the last year, Atea Pharmaceuticals shares have traded in a share price range of $ 2.765 to $ 5.19.

Atea Pharmaceuticals currently has 84,164,545 shares outstanding. The market capitalization of Atea Pharmaceuticals is $339.18 million. Atea Pharmaceuticals has a price to earnings ratio (PE ratio) of -2.49.

AVIR Latest News

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H’24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals...

Form 8-K - Current report

false 0001593899 0001593899 2024-02-28 2024-02-28     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT...

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400...

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

Form 4 - Statement of changes in beneficial ownership of securities

SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.143.589743589743.94.1353.775021053.98337731CS
4-0.46-10.22222222224.54.63.714257594.03152722CS
120.8526.64576802513.194.63.014947423.93984486CS
260.9731.59609120523.074.62.7654459153.49746836CS
520.928.66242038223.145.192.7654943963.68197663CS
156-55.27-93.188332490359.3163.382.765106736514.03166482CS
260-25.9-86.506346025429.9494.17372.76598617115.59550059CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
QLIQilian International Holding Group Ltd
$ 1.05
(52.20%)
2.84M
SBFMSunshine Biopharma Inc
$ 0.0821
(35.70%)
25.96M
GRTXGalera Therapeutics Inc
$ 0.1731
(23.64%)
1.26M
MEDPMedpace Holdings Inc
$ 480.00
(18.77%)
1.41k
JSPRWJasper Therapeutics Inc
$ 0.2147
(17.97%)
600
XTKGX3 Holdings Company Ltd
$ 0.646
(-34.75%)
1.32M
VVOSVivos Therapeutics Inc
$ 3.79
(-21.53%)
82.06k
NDRAENDRA Life Sciences Inc
$ 0.46
(-20.69%)
140.76k
KYCHKeyarch Acquisition Corporation
$ 10.00
(-18.70%)
9.97k
NVVENuvve Holding Corporation
$ 0.90
(-18.18%)
137.27k
SBFMSunshine Biopharma Inc
$ 0.0821
(35.70%)
25.96M
CRKNCrown Electrokinetics Corporation
$ 0.0606
(1.17%)
7.24M
AAPLApple Inc
$ 171.30
(-0.10%)
3.57M
JAGXJaguar Health Inc
$ 0.0872
(-3.00%)
3.5M
CISSC3is Inc
$ 0.0341
(-2.01%)
3.26M

AVIR Discussion

View Posts
DewDiligence DewDiligence 1 day ago
AVIR completes enrollment of phase-3 COVID trial—cancels interim analyses:

https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html Atea Pharmaceuticals…today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. Over 2,200 patients were randomized into the supportive care monotherapy cohort… The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients. The two planned interim analyses have been canceled: “Since full enrollment was achieved ahead of the two planned interim analyses for safety and futility by the Data Safety Monitoring Board (DSMB), the analyses are no longer relevant, and in agreement with the DSMB, we will proceed to the full analysis of the trial. We look forward to reporting SUNRISE-3 results in the second half of 2024…
👍️0
DewDiligence DewDiligence 4 weeks ago
AVIR phase-3 COVID update:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-fourth-quarter-210500983.html

The first and second interim analyses in the phase-3 COVID trial will be performed in March and in 2Q24, respectively, and the final results will be available in 2H24. 1,400 patients have been enrolled in the bemnifosbuvir monotherapy cohort (the cohort that the primary endpoint is based on).

AVIR had $578M of cash at 12/31/23, which is why they can afford to blow so much money on a longshot trial.
👍️0
DewDiligence DewDiligence 10 months ago
AVIR rejects Tang buyout offer, as expected:

https://www.globenewswire.com/news-release/2023/05/30/2678205/0/en/Atea-Pharmaceuticals%5B%E2%80%A6%5DTang-Capital-Partners-Affiliate-Concentra-Biosciences.html

The offer was for less than AVIR’s cash value.
👍️0
DewDiligence DewDiligence 10 months ago
It's not a serious offering for the reason mentioned in #msg-171974875.
👍️0
mwn mwn 10 months ago
Why is the sp going so far below the offering?
👍️0
DewDiligence DewDiligence 10 months ago
Yes.
👍️0
Paullee Paullee 10 months ago
Did you not notice that a CVR of 80% is included in the package?
👍️0
DewDiligence DewDiligence 10 months ago
In other words, AVIR could do better than $5.75/sh by simply liquidating.
👍️0
DewDiligence DewDiligence 10 months ago
AVIR acknowledges Tang buyout offer—makes_no_recommendation_to_shareholders—(yet):

https://www.globenewswire.com/news-release/2023/05/23/2674788/0/en/Atea-Pharmaceuticals-Confirms-Receipt-of-Unsolicited-Proposal-from-Tang-Capital-Partners-Affiliate-Concentra-Biosciences.html

Even thought Tang’s $5.75/sh offer is a big premium to where AVIR was trading prior to the offer, it’s less than AVIR’s cash value per share. Hence, it’s hard to see how AVIR’s BoD could accept the offer. They could make a counter-proposal, of course.
👍️0
DewDiligence DewDiligence 10 months ago
Tang Capital makes_unsolicited AVIR buyout offer@$5.75/sh +CVR—a_55%_premium_to_Friday’s_close:

https://www.sec.gov/Archives/edgar/data/1593899/000121465923007616/z519230sc13d.htm (scan to bottom)

Why does Tang want to acquire AVIR? Presumably for AVIR’s COVID drug, AT-527, such as it is. AT-527 is a polymerase inhibitor that is similar to an HCV drug BMY dropped several years ago due to toxicity. AVIR is conducting a phase-3 trial in high-risk COVID patients using a daily dose of 1100 mg (550mg BID); the trial listing is at: https://www.clinicaltrials.gov/ct2/show/NCT05629962 .
👍️0
Awl416 Awl416 10 months ago
Volume
👍️0
DewDiligence DewDiligence 11 months ago
AVIR 1Q23 CC transcript:

https://finance.yahoo.com/news/q1-2023-atea-pharmaceuticals-inc-140930636.html
👍️0
DewDiligence DewDiligence 11 months ago
AVIR 1Q23 results:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500951.html

3/31/23 cash = $621M.
👍️0
V63 V63 11 months ago
So AVIR beat its earnings, and now it might bump up a little tomorrow.
👍️0
DewDiligence DewDiligence 12 months ago
AVIR reports final data from phase-2 COVID trial:

https://www.globenewswire.com/news-release/2023/04/12/2645185/0/en/Atea-Announces-Presentation-of-Bemnifosbuvir-Data-Demonstrating-Reduced-Hospitalizations-for-COVID-19-Patients-at-2023-European-Congress-of-Clinical-Microbiology-Infectious-Disease.html
👍️0
DewDiligence DewDiligence 1 year ago
AVIR 4Q22 CC transcript:

https://finance.yahoo.com/news/atea-pharmaceuticals-inc-nasdaq-avir-022000995.html
👍️0
DewDiligence DewDiligence 1 year ago
AVIR 4Q22 results—12/31/22 cash=$647M:

https://www.globenewswire.com/news-release/2023/02/28/2617674/0/en/Atea-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

AVIR expects the interim analysis of the SUNRISE-3 (COVID) phase-3 trial to occur in 2H23. One possible outcome of the interim analysis is increasing the number of patients to provide more statistical power for the final analysis.
👍️0
DewDiligence DewDiligence 1 year ago
AVIR JPM webcast slides:

https://ir.ateapharma.com/static-files/731c461d-37e4-4364-8a12-eb605580b0aa
👍️0
DewDiligence DewDiligence 1 year ago
AVIR 2023 newsflow:

https://finance.yahoo.com/news/atea-pharmaceuticals-highlights-strategic-priorities-120000077.html
👍️0
DewDiligence DewDiligence 1 year ago
AVIR 3Q22 results—9/30/22 cash=$665M:

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-third-quarter-210500282.html

A phase-3 trial of Bemnifosbuvir (f/k/a AT-527) in 1,500 high-risk, non-hospitalized COVID patients is expected to start by the end of 2022. AVIR is defining “high-risk” as: a) age 80+; b) age 65+ with 1 or more major risk factors; or c) an immunocompromised adult of any age.

The daily dose of Bemnifosbuvir is a whopping 1100mg (550mg BID).
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 2Q22 results—6/30/22_cash=$684.5M (down from $705.5M at 3/31/22):

https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500782.html
👍️0
DewDiligence DewDiligence 2 years ago
AVIR 3/31/22 cash=$705.5M—burning $58.9M in 1Q22...

1Q22 PR:
https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-103000747.html

1Q22 CC slides:
https://ir.ateapharma.com/static-files/8a966559-367b-4a3b-96c0-ff21958c0562
👍️0
DewDiligence DewDiligence 2 years ago
LOL re AVIR’s attempt to be relevant:

https://www.globenewswire.com/news-release/2021/12/14/2352116/0/en/Atea-Pharmaceuticals-Introduces-New-Strategic-Clinical-Development-Program-for-AT-527-in-COVID-19.html
👍️0
Jake L Jake L 2 years ago
AVIR - Friday Rundown, Monday Expectations

👍️0
Wallst_junkie Wallst_junkie 2 years ago
Watching for a uptrend
👍️0
dealerschool2006 dealerschool2006 2 years ago
GOOD JOB!!! ya, by the time I discovered AVIR it had gone up 50% from the bottom...
👍️0
crudeoil24 crudeoil24 2 years ago
Wow! That's why you don't hold these Pharma overnight.

AVIR
👍️0
TheFinalCD TheFinalCD 2 years ago
wow went sub $11 and traded the whole float, shit it traded the whole OS 1.5x today https://finviz.com/quote.ashx?t=AVIR
👍️0
DewDiligence DewDiligence 2 years ago
Why AVIR's AT-527 program is no-go: #msg-166425975.
👍️0
XWAVXALMIMAN XWAVXALMIMAN 2 years ago
David v Goliath

Interesting article - check out RDHL

https://www.yahoo.com/entertainment/david-v-goliath-race-develop-123328764.html
👍️0
Chess Master Chess Master 2 years ago
What a drop
👍️0
ecommceo ecommceo 2 years ago
Way over sold here.
👍️0
Planopenny Planopenny 2 years ago
Out at $16, easy $$$
👍️0
Docstemcell2020 Docstemcell2020 2 years ago
Let's go Brandon! FJB :)
👍️0
DewDiligence DewDiligence 2 years ago
AVIR CC slides (largely BS, IMO):

https://ir.ateapharma.com/static-files/d72bd065-82b3-4eeb-ad3a-40c5518d66d6
👍️0
Planopenny Planopenny 2 years ago
In at $10
👍️0
rosemountbomber rosemountbomber 2 years ago
Well the shit just hit the fan. Didn’t meet primary in study. Stock dow $28
👍️0
rosemountbomber rosemountbomber 2 years ago
Thanks DD
👍️0
DewDiligence DewDiligence 2 years ago
The primary endpoint in MRK’s molnupiravir trial was the proportion of patients, relative to placebo, who died or needed hospitalization within 28 days:

https://clinicaltrials.gov/ct2/show/NCT04575597
👍️0
rosemountbomber rosemountbomber 2 years ago
So I have to confess to my ignorance when it comes to anti-viral clinical trials. It appears that the primary outcome studied in the AT-527 phase 3 trial is evaluated using a Covid 19 Symptom Diary. It does not sound like it is something very precise when asking a patient to score themselves on these 12 questions (which I have not exactly found yet).

But my question is, did the Merck drug molnupiravir get tested using this same method (symptom diary)? It must have been more than that at least as they also measure deaths, etc. - although that may have been secondary outcomes.
👍️0
Whalatane Whalatane 2 years ago
AVIR presentation tomorrow Oct 5th

https://newsfilter.io/articles/atea-pharmaceuticals-to-present-at-guggenheim-2nd-annual-vaccines--infectious-day-conference-42a958b2016103f267b2f6525ac4ac0c

Kiwi
👍️0
crudeoil24 crudeoil24 2 years ago
You bet! > AVIR up 45% @ 50.05
👍️0
Whalatane Whalatane 2 years ago
Thx for the updates

Kiwi
👍️0
crudeoil24 crudeoil24 2 years ago
AVIR up 45% @ 50.05 > premarket.
👍️0
crudeoil24 crudeoil24 2 years ago
AVIR > 53M share trading float.
👍️0
crudeoil24 crudeoil24 2 years ago
Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day Conference
7:00 am ET September 29, 2021 (Globe Newswire) Print
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will participate in a fireside chat at the Guggenheim 2nd Annual Vaccines & Infectious Day Conference on Tuesday, October 5, 2021 at 9:30 a.m. ET.

A live webcast of the presentation will be available here and on the Company's website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company's deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes

SVP, Investor Relations and Corporate Communications

617-818-2985

Barnes.jonae@ateapharma.com
👍️0
crudeoil24 crudeoil24 2 years ago
AVIR up 30% @ 45.00 > As Barron's reported in a magazine feature earlier this month , the pills have the potential to play an enormous role as the world adapts to an endemic threat from Covid-19. Even if the antivirals from Merck, Pfizer, the biotech Atea Pharmaceuticals (AVIR), and others, are only moderately effective, they are likely to be in enormous demand globally as patients and governments seek to blunt the human toll of the virus.
👍️0
DewDiligence DewDiligence 3 years ago
The stock is overvalued, IMO.
👍️0
rtrstock rtrstock 3 years ago
What is this chart going to do? It's fluctuations have it unreadable for me. Will this go back over 70?
👍️0
Paullee Paullee 3 years ago
Josh Nathan-Kazis
The mid-cap biotech Atea Pharmaceuticals is a frontrunner in the race to develop a Covid-19 antiviral, and its share price could double if an ongoing trial returns positive data, according to a note out early Thursday from SVB Leerink .
Atea (ticker: AVIR) is one of a number of companies developing Covid-19 antivirals, amid an emerging consensus that the virus that causes Covid-19 will remain a global health challenge for the long-term.
Big pharma giants Merck (MRK) and Pfizer (PFE) both are developing their own Covid-19 antiviral pills, but SVB Leerink analyst Roanna Ruiz writes in her Thursday note that the Covid-19 therapeutic market is "not a zero-sum game."
Atea's pill, known as AT-527, works differently from the Pfizer and Merck antivirals in development. The company is partnering with Roche (RHHBY) on development of the drug, which produced positive data in a Phase 2 trial. It is currently in a Phase 3 trial in non-hospitalized patients.
The trial is expected to produce data in the second half of this year. If those results are positive, Ruiz writes, they would be enough for the company to go to the U.S. Food and Drug Administration for emergency authorization.
If the FDA approves the drug, Ruiz projects that it could hit $2.3 billion in peak annual sales.
Ruiz initiated her coverage of the stock with an Outperform rating on Thursday and a $60 target price. The stock closed Wednesday at $27.70 and was up 0.2% on Thursday. Shares are down 33.6% this year amid a broader pullback among small and midcap biotech names.
In addition to the Phase 3 study of AT-527 in non-hospitalized patients with mild to moderate Covid-19, which will read out in the second half of this year, the company is running other trials of the drug, including one set to start this year that will test the drug as a prophylaxis. Ruiz estimates that the company could submit the drug for FDA authorization in late 2021 or early 2022.
"AT-527 could be one of the first approved oral antiviral therapies against Covid-19 and [key opinion leaders] are desperate for more convenient options," Ruiz wrote.
Amid the intense focus on Covid-19 vaccines, the effort to develop Covid-19 therapeutics has received substantially less attention. While a number of Covid-19 therapeutics do exist, all of the authorized options are either relatively ineffective or relatively inconvenient. The best available treatments, monoclonal antibody therapies from companies like Regeneron Pharmaceuticals (REGN), require patients to go to clinics to receive infusions.
In her note, Ruiz notes that Merck's molnupiravir may be ahead of AT-527 in terms of timing. Still, she writes that the market for a Covid-19 oral antiviral is big enough for more than one drug.
"We believe investors are watching molnupiravir and AT-527 closely, as both are in Phase 3 trials to treat outpatient COVID19; however, we do not think that this is a zero-sum game, and we think both orals would be used broadly in practice," Ruiz writes.
She says that Pfizer's oral antiviral, known as PF-00835231, may be a bit behind molnupiravir and AT-527, but is still a key competitor. "Despite it being slightly behind Merck/Atea, Pfizer's oral protease inhibitor could become a viable outpatient treatment option for COVID-19 if its antiviral efficacy is reiterated in the recently initiated larger Phase 2/3 trial," she writes.
Write to Josh Nathan-Kazis at josh.nathan-kazis@barrons.com
👍️0

Your Recent History

Delayed Upgrade Clock